Special Issue "SARS-CoV-2 Bioinformatics"

A special issue of COVID (ISSN 2673-8112).

Deadline for manuscript submissions: 6 May 2023 | Viewed by 1515

Special Issue Editor

1. Departamento de Ciências Biomoleculares, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil
2. Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC, USA
Interests: molecular biophysics; SARS-CoV-2 variants; structural bioinformatics; computer simulations; biomolecular engineering

Special Issue Information

Dear Colleagues,

SARS-CoV-2 emerged as a global threat and challenge. Throughout the COVID-19 pandemic and since its early days, computational works have been conducted from a better understanding of the virus to develop diagnostic tools, treatments, and vaccines. This was possible due to an already long history of success stories of computer simulations contributing to the understanding of complex systems in biology, pharmacology, and immunology. From the kinetics of the polymerization reaction of viruses and epidemiologic models to the design of antiviral molecules, a broad spectrum of studied phenomena illustrated the contributions from in silico works. A vast number of different theoretical approaches have been developed and applied and are nowadays boosted by the resurgence of artificial intelligence strategies. Rhinovirus, HIV, tobacco mosaic virus, Dengue, and Zika, among other systems, contribute to form this solid background for computational virology and immunoinformatics. Stepping on such a basis, the computational studies of SARS-CoV-2 together with the abundant source of experimental data promoted this research field to another level. Now is the time to highlight these in silico contributions and their importance in our fight against COVID-19. This is the main purpose of this Special Issue.

Moreover, often, theoretical papers are scattered in journals on different subjects due to the intrinsic multidisciplinary aspect of this research field. A Special Issue such as the present one offers the opportunity to portray the main contributions achieved at present in a single forum. Published in a common Special Issue, they can be a practical reference source for the topic and catalyze the cross-polymerization of the different computational approaches. High-quality scientific papers applying computational simulation methods to characterize any biological aspect of SARS-CoV-2, its infectivity, transmission, pathogenesis, diagnosis, treatments, and prevention are welcome. In particular, we would like to receive contributions that offer breakthrough contributions to the field. Works presenting new computational methods and tools are also welcome. Pure computational papers across different scales can be accepted providing they discuss the relevant experimental and/or clinical literature.

Dr. Fernando Barroso
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. COVID is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • computer simulation
  • molecular dynamics
  • Monte Carlo
  • artificial inteligence
  • docking
  • bioinformatics
  • Immunoinformatics
  • host-pathogen interactions
  • antibody
  • vaccine development

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Comparative Analysis and Classification of SARS-CoV-2 Spike Protein Structures in PDB
COVID 2023, 3(4), 452-471; https://doi.org/10.3390/covid3040034 - 29 Mar 2023
Viewed by 224
Abstract
The Spike (S) protein of the SARS-CoV-2 virus that causes the COVID-19 disease is considered the most important target for vaccine, drug and therapeutic research as it attaches and binds to the ACE2 receptor of the host cells and allows the entry of [...] Read more.
The Spike (S) protein of the SARS-CoV-2 virus that causes the COVID-19 disease is considered the most important target for vaccine, drug and therapeutic research as it attaches and binds to the ACE2 receptor of the host cells and allows the entry of this virus. Analysis and classification of newly determined S protein structures for SARS-CoV-2 are critical to properly understand their functional, evolutionary and architectural relatedness to already known protein structures. In this paper, first, the comparative analysis of SARS-CoV-2 S protein structures is performed. Through comparative analysis, the S protein structures in the PDB (protein data bank) database are compared and analyzed not only with each other but with the structures of other viruses for various parameters. Second, the S protein structures in PDB are classified into different variants, and the associated published literature is studied to investigate what kind of therapeutics (antibodies, T-cell receptors and small molecules) are used on the structures. This is the first study that classifies the S protein structures of the SARS-CoV-2 in PDB into various variants, and the obtained comparative analysis results could be beneficial to the research community, in general, and to crystallographers and health workers, in particular. Full article
(This article belongs to the Special Issue SARS-CoV-2 Bioinformatics)
Show Figures

Figure 1

Article
In Silico Screening of Prospective MHC Class I and II Restricted T-Cell Based Epitopes of the Spike Protein of SARS-CoV-2 for Designing of a Peptide Vaccine for COVID-19
COVID 2022, 2(12), 1731-1747; https://doi.org/10.3390/covid2120124 - 30 Nov 2022
Viewed by 839
Abstract
Multiple vaccines were developed and administered to immunize people worldwide against SARS-CoV-2 infection. However, changes in platelet count following the course of vaccination have been reported by many studies, suggesting vaccine-induced thrombocytopenia. In this context, designing an effective targeted subunit vaccine with high [...] Read more.
Multiple vaccines were developed and administered to immunize people worldwide against SARS-CoV-2 infection. However, changes in platelet count following the course of vaccination have been reported by many studies, suggesting vaccine-induced thrombocytopenia. In this context, designing an effective targeted subunit vaccine with high specificity and efficiency for people with low platelet counts has become a challenge for researchers. Using the in silico-based approaches and methods, the present study explored the antigenic epitopes of the spike protein of SARS-CoV-2 involved in initial binding of the virus with the angiotensin converting enzyme-2 receptor (ACE-2) on the respiratory epithelial cells. The top ten major histocompatibility complex-I (MHC-I) and MHC-II restricted epitopes were found to have 95.26% and 99.99% HLA-class-I population coverage, respectively. Among the top ten promiscuous MHC-I restricted epitopes, ’FTISVTTEI’ had the highest global HLA population coverage of 53.24%, with an antigenic score of 0.85 and a docking score of −162.4 Kcal/mol. The epitope ‘KLNDLCFTNV’ had the best antigenic score of 2.69 and an HLA population coverage of 43.4% globally. The study predicted and documented the most suitable epitopes with the widest global HLA coverage for synthesis of an efficient peptide-based vaccine against the deadly COVID-19. Full article
(This article belongs to the Special Issue SARS-CoV-2 Bioinformatics)
Show Figures

Figure 1

Back to TopTop